20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.
15 citations
,
July 2022 in “Biomedicines” This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.
4 citations
,
June 2023 in “Frontiers in immunology” This study found that JAK inhibitors effectively improve alopecia areata outcomes, as indicated by SALT scores, but they were associated with an increased risk of adverse effects, with 921 out of 1508 patients experiencing adverse reactions.
3 citations
,
March 2025 in “Journal of Clinical Medicine” This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.
2 citations
,
September 2024 in “Journal of Dermatological Treatment” In this study, combining compound glycyrrhizin with topical minoxidil was more effective and as safe as minoxidil alone for treating alopecia areata.